Predicted effectiveness of vaccines and extended half-life monoclonal antibodies against RSV hospitalizations in children.

ABSTRACT: Several vaccines and extended half-life monoclonal antibodies (mAbs) against respiratory syncytial virus (RSV) have shown promise in clinical trials. We used age-structured transmission models to predict the possible impact of various RSV prevention strategies including maternal immunization, live-attenuated vaccines, and long-lasting mAbs. Our results suggest that maternal immunization and long-lasting mAbs are likely to be highly effective in preventing RSV hospitalizations in infants under 6 months of age, averting more than half of RSV hospitalizations in neonates. Live-attenuated vaccines could reduce RSV hospitalizations in vaccinated age groups and are also predicted to have a modest effect in unvaccinated age groups because of disruptions to transmission. Compared to year-round vac

SUBMITTER: Zheng Z 

PROVIDER: S-EPMC9612629 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature